{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-034736","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.100471+00:00","generated_at":"2026-05-31T13:18:42.968734+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Delcath Q2 revenue $7.8M vs $0.5M YoY; HEPZATO KIT generates $6.6M","bullets":["Revenue $7.8M ($6.6M HEPZATO US, $1.2M CHEMOSAT Europe) vs $0.5M prior year.","Cash and investments $19.9M; final principal payment submitted to Avenue Venture.","Activated 8 US treating centers; received CMS NTAP status for HEPZATO (Aug 1, 2024).","Appointed Dr. Bridget Martell to Board; extended melphalan supply agreement to 2028.","FOCUS study results published in Annals of Surgical Oncology; accepted for ESMO poster."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-034736","json":"https://secwatch.observer/filing/0001628280-24-034736.json","markdown":"https://secwatch.observer/filing/0001628280-24-034736.md","text":"https://secwatch.observer/filing/0001628280-24-034736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000162828024034736/0001628280-24-034736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000162828024034736/dcth-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:18:42.968734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}